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Introduction
Breast cancer is predominantly a female disease with 
49,492 cases (invasive and non-invasive) diagnosed in the 
UK in 2006 [1]. According to data from the International 
Agency for Research on Cancer, this is broadly in line 
with ﬁ  gures from other western nations [2]. Tremendous 
strides in our understanding of breast cancer have been 
made over the past two decades and, when detected early, 
breast cancer is one of the most curable and treatable of 
all cancers. Male breast cancer is much less frequent with 
334 cases diagnosed in the UK in 2006 [1], accounting for 
just under 1% of all breast cancers.
Risk factors for male breast cancer
Owing to the rarity of male breast cancer, establishing 
precise risk factors for the disease has proved challenging. 
Male and female breast cancers share many common risk 
factors; for example, advancing age and previous family 
history. In terms of male breast cancer, data from the 
Breast Cancer Linkage Consortium showed that men 
harbouring BRCA2 mutations have a relative risk of 80 
for developing breast cancer [3] – making BRCA2 the 
strongest known gene associated with male breast cancer 
[4,5]. Androgen receptor mutations have also been 
reported [6]. Some suggested risk factors associated with 
male breast cancer are summarised in Table 1 [4-8].
Increasing incidence of male breast cancer
Although still a rare disease, anecdotal evidence from 
clinical and pathology colleagues coupled with reports 
from recent literature suggests that male breast cancer is 
becoming more common [9-12]. As a means of corro  bor-
at  ing this, we analysed data from four western nations: 
England, Scotland, Canada and Australia. Data for 
England were provided by the West Midlands Cancer 
Intelligence Unit [13]. Data for Scotland were obtained 
from the Information Services Division (Scotland) 
website [14]. Canadian data were obtained from the 
Public Health Agency of Canada [15], and data for 
Australia from the Australian Institute of Health and 
Welfare [16]. As the population of Scotland is 
considerably smaller than the other three nations, 
Scottish and English data were combined. Data were 
collected over a 15-year period (1991 to 2005) and were 
presented as absolute numbers and as World Health 
Organisation World Age Standardised Rates. Data for 
England were also available over a 20-year period (1986 
to 2006).
As shown in Figure 1, our observations clearly show 
that the number of cases of invasive male breast carci-
noma diagnosed over a 15-year period has consistently 
increased in all countries. As well as increases in absolute 
numbers, age-adjusted incidence increased from 0.4 to 
0.6 (England/Scotland), from 0.5 to 0.8 (Canada) and 
from 0.6 to 0.7 (Australia) per 100,000 population. 
Similar trends were observed when absolute numbers for 
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incidence of one-third was observed from 185 cases in 
1986 to 277 cases in 2006, which corresponded to 0.5 per 
100,000 population in 1986 (95% conﬁ  dence interval, 0.4 
to 0.6) and to 0.7 per 100,000 population in 2006 (95% 
conﬁ  dence interval, 0.6 to 0.7). A limitation in our data 
was incomplete information on the stage of disease at 
presentation, and while increases observed in absolute 
numbers do not account for changing denominators over 
time, congruent changes in the age-adjusted incidence 
give conﬁ  dence that these changes are real. Furthermore, 
our data parallel Surveillance, Epidemiology and End 
Results data published in 2004 showing that male breast 
carcinoma rates rose by 25% over a 26-year period [9] 
and extend our earlier observation that was limited to a 
subset of UK cancer registries [12].
In the absence of formal epidemiological studies, reasons 
for the apparent rise in male breast cancer incidence can 
only be speculated. It is well recognised that lifestyle 
changes over the latter decades of the 20th century have 
led to increased obesity in western nations, which is 
rapidly becoming a global problem. Th   is may be a contri-
buting factor as obesity is linked to cancer predisposition, 
and breast cancer is no exception [17,18]. Increased 
alcohol intake is associated with increased relative risk of 
breast cancer [19], which may also play a role. Much 
more controversially, increased exposure to so-called 
environmental oestrogens via diet and household 
products have been mooted as potential risk factors for 
breast cancer development [20], but there are no 
substantive data to support this.
Clinical management of male breast cancer
General strategies
Th  e general approach for managing early male breast 
cancer is the same as that recommended for women. Th  e 
therapeutic modalities employed include surgery, radio-
therapy and systemic therapies. As many excellent expert 
overviews on the subject exist [9,11,21], here we present 
only a brief summary. Surgical removal of the primary 
tumour by mastectomy or, rarely, by wide local excision is 
often accompanied by axillary node dissection, or, more 
recently, sentinel lymph node biopsy [22]. Adjuvant 
radiotherapy to the chest wall and draining lymphatic 
basin is often advised, especially in high-risk node-
positive groups, with the aim of reducing loco-regional 
recurrence, although there is a general lack of consensus 
on the optimal regimen [11]. Systemic therapies include 
chemotherapy, oral endocrine agents and, more recently, 
trastuzumab. Information on the potential beneﬁ  t  of 
adjuvant chemotherapy in men is also scarce, although 
the few published data support its use as the proportion 
of response is similar in males to that in females [23,24].
Endocrine therapies
Th   e importance of hormone manipulation in the 
manage  ment of male breast cancer was recognised as 
early as the 1940s when orchidectomy was ﬁ  rst described 
as a treatment for skeletal metastases [25]. Patients 
persuaded to undergo orchidectomy were reported to 
experience rapid and dramatic relief of pain due to bony 
metastases. Proven regression of pulmonary metastases 
was demonstrated radiologically. Orchidectomy was also 
shown to elicit regression of the primary tumour in cases 
where it had not been removed surgically [26]. Other 
surgical procedures to alter the hormonal environment 
such as hypophysectomy and adrenalectomy have also 
been used. Th   ese were seen to be eﬀ  ective to some extent 
in the prevention of progression of metastatic disease but 
were not commonly used in the adjuvant setting. A meta-
analysis of published case series of male patients with 
metastatic disease reported tumour regression rates of 
55% for orchidectomy (n = 355), 80% for adrenalectomy 
(n = 65) and 56% for hypophysectomy (n = 27), with an 
overall response rate of 59% in 447 patients [27]. Th  ese 
results should be interpreted with caution given that 
Table 1. Suggested risk factors for male breast cancer
Risk factor  Explanation
BRCA2  BRCA2 mutations are associated with most inherited MBC
Klinefelter syndrome  Hereditary condition characterised by the 47XXY karyotype, which is consistently associated with MBC
Androgen receptor mutation  Germline mutations in AR predispose to MBC
CYP17  Encodes cytochrome P450c17α, an enzyme involved in oestrogen and androgen biosynthesis
Cowden syndrome  Autosomal-dominant cancer susceptibility syndrome caused by germline mutation in the PTEN gene
CHEK2  CHEK2*1100delC variants may increase risk of MBC by 10-fold
Endogenous oestrogen levels  Increased oestrogen levels as a result of obesity, male–female transsexuals and liver cirrhosis are all associated with MBC
Testicular disorders  Cryptorchidism, mumps orchitis, orchiectomy, congenital inguinal hernia and testicular injury are associated with MBC
Physical inactivity  Lack of exercise is associated with increased risk of MBC
Data obtained from [3-7]. These references include comprehensive discussion on other considered risk factors for male breast cancer (MBC). CHEK, cell-cycle 
checkpoint kinase.
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Page 2 of 7Figure 1. Male breast cancer incidence diagnosed over a 15-year period. Number of cases of invasive male breast carcinoma in 
(a), (b) England/Scotland, (c), (d) Canada and (e), (f) Australia, 1991 to 2005. (a), (c), (e) Absolute numbers. (b), (d), (f) Age-adjusted rates.
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measured, was not clearly deﬁ  ned in the meta-analysis. 
Nowadays, such invasive procedures are seldom, if ever, 
carried out, having been superseded by more advanced 
medical treatments.
Th   ere is conclusive evidence regarding the importance 
of oestrogen receptor measurement in female breast 
cancer, as the absence of receptors accurately predicts 
lack of sensitivity to endocrine therapy. As hormone 
receptor positivity for both oestrogen receptor and 
proges  terone receptor is proportionally higher in male 
breast cancer than female breast cancer [28,29], hormone 
therapies should be at least as eﬀ  ective in male breast 
cancer patients – thus most male breast cancer patients 
receive endocrine therapy.
Tamoxifen became established as part of the routine 
management of breast cancer in the 1970s [30]. 
Tamoxifen’s eﬃ   cacy in male breast cancer was ﬁ  rst shown 
in a study of 24 patients, where tamoxifen treat  ment 
produced disease regression of 37.5%, and was eﬀ  ective 
in treating metastases in soft-tissues, bone and lung [31]. 
Another study conducted on 41 patients also concluded 
that hormone therapy was successful in treating male 
breast cancer [32]. Further study has demonstrated that 
men treated with tamoxifen have a 51% lower risk of 
recurrence, comparable with that seen in women [28,33]. 
Although this evidence is from relatively small retro-
spective studies or extrapolated from results in trials 
treating females with breast cancer, due to its eﬃ   cacy and 
low cost, tamoxifen has gained widespread acceptance as 
the standard endocrine therapy in the treatment of 
hormone-sensitive male breast carcinoma [29,33,34]. 
Nevertheless, treatment with tamoxifen is associated 
with a multitude of side eﬀ  ects in men. Common prob-
lems include hair loss, skin rash, impotence, decreased 
libido, weight gain, hot ﬂ  ushes, mood changes, depres-
sion and insomnia. Th  e incidence of these side eﬀ  ects 
may be as high as 62% and perhaps explains why compli-
ance with tamoxifen is often poor [35].
Th  e discovery that oestrogens are produced locally in 
breast tissues, by aromatisation of other sex steroid 
hormones [36], led to concerted eﬀ  orts to exploit this 
pathway as a potential therapeutic target. Unlike tamoxi-
fen, which is a selective oestrogen receptor modulator, 
aromatase inhibitors (AIs) prevent the conversion of 
androstenedione to 17β-estradiol. Data from large ran-
dom  ised clinical trials in females with breast cancer, in 
which the eﬃ   cacy of AIs was compared with tamoxifen 
as an initial adjuvant endocrine therapy, or sequential 
(adjuvant tamoxifen or AI in either order) or extended 
(AI after 5 years of adjuvant tamoxifen) therapy, demon-
strated a reduced risk of breast cancer recurrence com-
pared with 5 years of tamoxifen treatment alone. AIs are 
now con  sidered the therapy of choice for postmenopausal 
women with oestrogen receptor-positive breast cancer 
[37].
Th   e use of AIs in male breast cancer was proposed due 
to their success in females and the identiﬁ  cation of intra-
tumoural aromatase in male breast cancer [38,39]. 
Despite hopes that aromatase inhibition would be useful 
in the management of metastatic disease in men, initial 
case series have disappointingly shown negative or 
equivocal results. In a series of ﬁ  ve patients, none showed 
an objective response to treatment with anastrozole [40]. 
Interestingly, however, there have been three reported 
individual cases of response to letrozole alone in men 
[41-43]. In a recent Canadian study, eight male breast 
cancer patients were treated with anastrozole (three in 
the adjuvant setting and ﬁ  ve in the metastatic setting), 
with three of the cohort experiencing side eﬀ  ects 
including depression, decreased libido and lower-limb 
oedema [44]. In the same series, letrozole was prescribed 
to ﬁ   ve patients in the metastatic setting after prior 
tamoxifen treatment, with two out of ﬁ  ve experiencing 
oedema. Despite these side eﬀ  ects, none of the patients in 
this study dis  continued treatment with either of these AIs.
In animal models, aromatase inhibition increases levels 
of follicle-stimulating hormone and testosterone but 
oestrogen levels are almost unchanged [45]. Moreover, a 
fall in oestrogen levels of 50% was seen in studies where 
anastrozole was given to healthy male volunteers, but this 
is not as dramatic as in females where AIs were shown to 
cause a 98% reduction. Administration of anastrozole in 
men, however, was also associated with a signiﬁ  cant 
increase of 58% in the levels of circulating testosterone 
[46]. By contrast, adminis  tered at a similar dose to that 
used in women, letrozole treatment resulted in a 70 to 
80% reduction in oestrogen levels in men [47]. Given that 
around 20% of circulating oestrogen is produced by the 
testis, this represents an almost total blockade of 
peripheral aromatisation.
In what is, to date, the most extensive description of 
the use of AIs for metastatic male breast cancer in the 
literature, Doyen and colleagues reported a complete 
tumour response in 13% (two patients), partial response 
in 27% (four patients), stable disease in 13% (two patients) 
and progressive disease in 47% (seven patients) [48]. Only 
six of the 15 patients in this study were assessed with 
regard to their serum oestrogen levels. In each of these 
cases, oestrogen levels fell below the minimum limit of 
detection after commencement of AI. Th  e treatment 
response in this group varied, with three patients having 
partial response, one patient having stable disease and 
two patients showing progression [48]. Understanding 
why progression occurs in the almost complete absence 
of oestrogen requires further investigation.
Th  e increase in testosterone seen after aromatase 
inhibition has been suggested to eﬀ  ectively overcome the 
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pathway with substrate, leading to only modest reduction 
in serum oestrogen. Combination therapy with a 
gonadotrophin-releas  ing hormone agonist eﬀ  ectively 
reduces the excess substrate and maximises the eﬀ  ect of 
aromatase inhibi  tion, and has been seen to cause regres-
sion in male patients with disease refractory to aromatase 
inhibition alone [49]. Th  is observation requires further 
evaluation and may allow more frequent use of AIs in 
males, possibly in combination with a gonadotrophin-
releasing hormone agonist. Th  e SWOG-S0511 trial – a 
small, phase 2 trial of 56 patients with recurrent or 
metastatic disease, in which goserelin is administered 
subcuta  neously on day 1 followed by oral anastrozole for 
28 days for 12 cycles – has been designed to help answer 
these questions [50]. Th   is trial has completed recruitment 
and the results are awaited.
Other available endocrine therapies include the pure 
anti-oestrogen fulvestrant, a selective oestrogen receptor 
downregulator, currently only licensed for use in ad-
vanced breast cancer in women. Th  ere are only three 
reports of its success in metastatic male breast cancer 
[51-53]. Th  e most recent study evaluated ﬁ  ve patients 
with metastatic disease and observed either partial res-
ponse or disease stability in three out of ﬁ  ve patients, 
concluding that fulvestrant should be considered as a 
treatment option in pretreated metastatic male breast 
cancer patients [53].
Other potential therapeutic strategies
Although not exclusive to male breast cancer, other 
putative novel therapeutic targets include prolactin 
receptor and androgen receptor. Th  e presence of pro-
lactin receptor in both benign and malignant male breast 
tissue varies according to the site of expression; benign 
lesions only express the receptors on the luminal surface 
of epithelial cells, while malignant lesions show cyto-
plasmic expres  sion [54-56]. Moreover, male breast cancer 
was reported in the context of hyperprolactinaemia [57]. 
Owing to local production of prolactin in breast tissue, 
where it acts as a paracrine hormone [58], the potential 
of the targeting pathway as a putative therapeutic target 
is receiv  ing increased attention [59]. A study of 251 male 
breast cancers indicated a potential role for androgen 
receptor as a therapeutic target following the association 
of androgen receptor positivity with better outcome [60], 
paralleling similar observations in a series of 953 female 
breast cancers [61] – suggesting that there is potential to 
explore anti-androgen therapies as a therapeutic approach.
Public education
Th  e general public consider breast cancer very much a 
female disease, and a diagnosis of male breast cancer is 
often met with a sense of disbelief [62]. Pink ribbon 
campaigns have been hugely successful at promoting 
breast cancer awareness on an international level and, 
although direct evidence is lacking, these campaigns may 
have contributed to earlier detection, which makes the 
disease much more treatable. However, these campaigns 
remain very much female focused. Th  e pink and blue 
ribbon developed by the John W Nick Foundation is 
aimed at promoting breast cancer awareness in men [63]. 
As male breast cancer incidence is undoubtedly rising, it 
would seem sensible to promote this in tandem with pink 
ribbons as a way of educating the public about the disease 
in men.
Conclusion
Although rates of male breast cancer are increasing, the 
cancer remains rare. Few direct epidemiological or 
clinical trial data are thus available and nearly all infor-
mation used in understanding male breast cancer comes 
from studies of female breast cancer, which undoubtedly 
provides an inaccurate picture. More recently, gender-
related diﬀ  erences in gene proﬁ  les have been reported 
[64,65]. Although both studies emphasised caveats asso-
ciated with their cohort sizes, the diﬀ  erences reported 
provide a stimulus to dissect out potential diﬀ  erences in 
the biology of male and female breast cancer. In addition, 
two very timely articles outlining the development of the 
Male Breast Cancer Consortium [66] and an International 
Male Breast Cancer Program [67] oﬀ  er further hope for 
much-needed progress. Both studies will examine 
biomarker proﬁ  les in male breast cancer, with the latter 
oﬀ  ering the additional prospect of a male breast cancer-
speciﬁ  c clinical trial. Whilst accrual is likely to be slow, 
international eﬀ   ort can only facilitate this. Th  ese 
collections will provide important resources for the study 
of male breast cancer, something we consider is much 
needed in order to advance our understanding of the 
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